Literature DB >> 20798915

[The concept of the development of S3 guidelines: additional benefit compared to traditional standards, problems and solutions].

A Pfennig1, I Kopp, D Strech, M Bauer.   

Abstract

Guidelines for the diagnosis and treatment of psychiatric disorders developed on the highest qualitative methodical standard cover reliable decision guidance and are an important instrument of quality improvement in health care. They have to be accessible with little effort and should be concise and clearly presented to be used in daily routine. Early integration of members of the different professions, patients and their care givers into the development process is essential for acceptance. The development process of a S3 guideline is complex and poses a difficult challenge to personal manpower and funding, which is met by the associations of the Association of Medical Societies in Germany. Further scientific discussion is necessary to find adequate solutions for problematic topics or potential distortion, such as the consequences of inadequate reporting of studies, insufficient recording and reporting of the risk of damage, unpublished data and lacking interest of sponsors in specific topics.

Entities:  

Mesh:

Year:  2010        PMID: 20798915     DOI: 10.1007/s00115-010-3085-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  18 in total

1.  The hazards of scoring the quality of clinical trials for meta-analysis.

Authors:  P Jüni; A Witschi; R Bloch; M Egger
Journal:  JAMA       Date:  1999-09-15       Impact factor: 56.272

2.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

3.  Developing valid guidelines: methodological and procedural issues from the North of England Evidence Based Guideline Development Project.

Authors:  M Eccles; Z Clapp; J Grimshaw; P C Adams; B Higgins; I Purves; I Russell
Journal:  Qual Health Care       Date:  1996-03

4.  [Perspectives in guideline development and implementation in Germany].

Authors:  I B Kopp
Journal:  Z Rheumatol       Date:  2010-06       Impact factor: 1.372

Review 5.  Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?

Authors:  Su Golder; Yoon K Loke
Journal:  Br J Clin Pharmacol       Date:  2008-07-31       Impact factor: 4.335

6.  [Development of the evidence-based S3 guideline for diagnosis and therapy of bipolar disorders].

Authors:  Andrea Pfennig; Beate Weikert; Peter Falkai; Thomas Gotz; Ina Kopp; Johanna Sasse; Harald Scherk; Daniel Strech; Michael Bauer
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

7.  [Self-help groups conflicts of interest through sponsoring by the pharmaceutical industry].

Authors:  D Klemperer
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2009-01       Impact factor: 1.513

8.  Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies.

Authors:  Fujian Song; Sheetal Parekh-Bhurke; Lee Hooper; Yoon K Loke; Jon J Ryder; Alex J Sutton; Caroline B Hing; Ian Harvey
Journal:  BMC Med Res Methodol       Date:  2009-11-26       Impact factor: 4.615

9.  [Consensus development in evidence-based guidelines: from myths to rational strategies].

Authors:  Ina B Kopp; Hans-Konrad Selbmann; Michael Koller
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2007

10.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

View more
  6 in total

1.  [A new evidence and consensus-based German guidelines for diagnosis and treatment of bipolar disorders].

Authors:  M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

2.  [S3 guidelines on bipolar disorders are contemporary and important instruments for clinical practice. For].

Authors:  A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

3.  [Treatment of Alzheimer's disease according to the S3 guidelines on dementia. Choline esterase inhibitors for all and for ever?].

Authors:  Thomas Lempert; Tom Bschor
Journal:  Nervenarzt       Date:  2011-01       Impact factor: 1.214

4.  [Quality of reporting in studies on bipolar disorders: implications for the development of guidelines].

Authors:  B Soltmann; A Pfennig; B Weikert; M Bauer; D Strech
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

Review 5.  The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline.

Authors:  Andrea Pfennig; Tom Bschor; Peter Falkai; Michael Bauer
Journal:  Dtsch Arztebl Int       Date:  2013-02-08       Impact factor: 5.594

6.  [S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations].

Authors:  A Pfennig; T Bschor; T Baghai; P Bräunig; P Brieger; P Falkai; D Geissler; R Gielen; H Giesler; O Gruber; I Kopp; T D Meyer; K H Möhrmann; C Muche-Borowski; F Padberg; H Scherk; D Strech; M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.